Aspergillosis News and Research

RSS

Study: Fungal asthma in UK greatly exceeds prior estimates

Experts are warning of a significant increase in the number of people in the UK who are living with invasive and serious fungal diseases that affect the lungs, bloodstream and brain and can sometimes lead to death.

16 Nov 2016

Aflatoxin exposure can weaken airways' defenses opening door for severe respiratory diseases

Toxins from mold found growing on nuts or corn can weaken the airways' self-clearing mechanisms and immunity, opening the door for respiratory diseases and exacerbating existing ones, suggests a study in Nature Scientific Reports published this month from otolaryngology researchers at the Perelman School of Medicine at the University of Pennsylvania.

27 Sep 2016

New IDSA guidelines focus on diagnosis, treatment of deadly aspergillosis

New therapies are improving care, but early diagnosis remains critical in the effective treatment of invasive, a potentially deadly fungal infection, according to new guidelines released by the Infectious Diseases Society of America and published in the journal Clinical Infectious Diseases.

30 Jun 2016

New clinical imaging method may enable doctors to tackle lung infections

A new clinical imaging method developed in collaboration with a University of Exeter academic may enable doctors to tackle one of the main killers of patients with weakened immune systems sooner and more effectively.

19 Jan 2016

Researchers discover new way for early detection of potentially deadly fungal infection in leukemia patients

A team of researchers have discovered a new way for early detection of a potentially deadly fungal infection in patients with suppressed immune systems such as those being treated for leukemia or have had an organ transplant.

15 Dec 2015

Common drug used for treating fungal infections in lung transplant recipients increases risk for skin cancer, death

Voriconazole, a prescription drug commonly used to treat fungal infections in lung transplant recipients, significantly increases the risk for skin cancer and even death, according to a new study by UC San Francisco researchers.

3 Sep 2015

Astellas reports topline results from isavuconazole Phase 3 study in candidemia and other invasive Candida infections

Astellas today announced topline results from the Phase 3 ACTIVE study evaluating the efficacy and safety of intravenous (IV) and oral isavuconazole, commercially known as CRESEMBA (isavuconazonium sulfate), under development for adults with candidemia and other invasive Candida infections.

30 Jul 2015

New type of mycovirus can cause aspergillosis in humans

Researchers, led by Dr Robert Coutts, Leverhulme Research Fellow from the School of Life and Medical Sciences at the University of Hertfordshire, and Dr Ioly Kotta-Loizou, Research Associate at Imperial College, have discovered a completely novel type of mycovirus.

29 Jul 2015

Europe has increasing prevalence of fungal resistance, warns ESCMID

The European Society of Clinical Microbiology and Infectious Disease – an organization that explores the risks and best practices in infectious disease – is imploring global healthcare professionals and bodies to take a more active role in the growing problem of fungal resistance.

28 Jul 2015

FDA approves Astellas' CRESEMBA for treatment of invasive aspergillosis, invasive mucormycosis

Astellas today announced that the U.S. Food and Drug Administration has approved its New Drug Application (NDA) for the use of CRESEMBA (isavuconazonium sulfate), the prodrug for isavuconazole, for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis (also known as zygomycosis).

8 Mar 2015

Leading microbiologist warns of killer fungi’s increasing threat

A leading microbiologist has warned of the increasing threat that killer fungi poses to humans and the environment.

15 Jan 2015

Astellas' isavuconazole gets FDA orphan drug designation for treatment of invasive candidiasis

Astellas announced today that the U.S. Food and Drug Administration has granted orphan drug designation to isavuconazole for the treatment of invasive candidiasis.

3 Nov 2014

Pulmocide uses INTEGRA's VIAFLO Assist pipetting assistant to improve screening of novel compounds

INTEGRA reports on how respiratory drug discovery and development specialists - Pulmocide Ltd. (London, UK) are using a VIAFLO Assist pipetting assistant to enhance the productivity and reproducibility of their screening of novel compounds in a range of biological assays.

From INTEGRA Biosciences 28 Oct 2014

Novel approach may help detect invasive aspergillosis

Many different microbes can cause pneumonia, and treatment may be delayed or off target if doctors cannot tell which bug is the culprit. A novel approach—analyzing a patient's breath for key chemical compounds made by the infecting microbe—may help detect invasive aspergillosis, a fungal infection that is a leading cause of mortality in patients with compromised immune systems, according to a proof-of-concept study now online in Clinical Infectious Diseases.

23 Oct 2014

Isavuconazole demonstrates successful outcomes in treatment of mucormycosis

Astellas reported today that isavuconazole demonstrated successful outcomes in the treatment of mucormycosis according to data from the phase 3 isavuconazole VITAL study being presented at IDWeek on October 10, 2014, in Philadelphia, Pa.

8 Oct 2014

New antifungal drug effective against invasive mold disease in cancer patients with less adverse effects

A newly developed antifungal, isavuconazole, is as effective as an existing drug, voriconazole, against invasive mold disease in cancer patients with less adverse effects, according to phase 3 clinical data presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, an infectious disease meeting of the American Society for Microbiology.

8 Sep 2014

F2G begins F901318 Phase I clinical study for treatment of aspergillus infections

F2G Limited, the antifungal research and development company today announced a major milestone in the development of its novel IV/ oral systemic antifungal (F901318) with the commencement of a Phase I clinical study.

4 Sep 2014

Combination of NASBA and real-time qPCR detects aspergillosis with 100% accuracy

The fungal infection invasive aspergillosis (IA) can be life threatening, especially in patients whose immune systems are weakened by chemotherapy or immunosuppressive drugs. Despite the critical need for early detection, IA remains difficult to diagnose.

14 Aug 2014

Scientist develops highly accurate device for diagnosing fatal lung disease

A scientist from the University of Exeter has developed a simple, cheap and highly accurate device for diagnosing a frequently fatal lung disease which attacks immune deficient individuals such as cancer patients and bone marrow transplant recipients.

24 Jul 2014

FDA designated Astellas’ isavuconazole as QIDP for treatment of invasive candidiasis

Astellas today announced that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive candidiasis, a life-threatening, invasive fungal infection.

17 Jul 2014